Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001916418 | SCV002178016 | uncertain significance | MHC class I deficiency | 2022-07-12 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 269 of the TAP2 protein (p.Asn269Ser). This variant is present in population databases (rs572376231, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with TAP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1410382). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004681314 | SCV005167603 | uncertain significance | Inborn genetic diseases | 2024-05-13 | criteria provided, single submitter | clinical testing | The c.806A>G (p.N269S) alteration is located in exon 5 (coding exon 4) of the TAP2 gene. This alteration results from a A to G substitution at nucleotide position 806, causing the asparagine (N) at amino acid position 269 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |